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OBJECTIVEdIn clinical trials, diet, exercise, and weight counseling led to short-term
improvements in blood glucose, blood pressure, and cholesterol levels in patients with diabetes.
However, little is known about the long-term effects of lifestyle counseling on patients with
diabetes in routine clinical settings.
RESEARCH DESIGN AND METHODSdThis retrospective cohort study of 30,897
patients with diabetes aimed to determine whether lifestyle counseling is associated with time
to A1C, blood pressure, and LDL cholesterol control in patients with diabetes. Patients were
included if they had at least 2 years of follow-up with primary care practices afﬁliated with two
teaching hospitals in eastern Massachusetts between 1 January 2000 and 1 January 2010.
RESULTSdComparing patients with face-to-face counseling rates of once or more per month
versus less than once per 6 months, median time to A1C ,7.0% was 3.5 versus 22.7 months,
time to blood pressure ,130/85 mmHg was 3.7 weeks versus 5.6 months, and time to LDL
cholesterol ,100 mg/dL was 3.5 versus 24.7 months, respectively (P , 0.0001 for all). In
multivariable analysis, one additional monthly face-to-face lifestyle counseling episode was as-
sociated with hazard ratios of 1.7 for A1C control (P , 0.0001), 1.3 for blood pressure control
(P , 0.0001), and 1.4 for LDL cholesterol control (P = 0.0013).
CONCLUSIONSdLifestylecounselingintheprimarycaresettingisstronglyassociatedwith
faster achievement of A1C, blood pressure, and LDL cholesterol control. These results conﬁrm
that the ﬁndings of controlled clinical trials are applicable to the routine care setting and provide
evidence to support current treatment guidelines.
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D
iabetes is increasingly common in
the U.S. and worldwide (1,2). Ele-
vatedbloodglucose,bloodpressure,
and LDL cholesterolareassociated within-
creased risk for micro- and macrovascular
complications, and their reduction de-
creases the risk (3–8). Nevertheless, most
patients with diabetes do not have A1C,
blood pressure,and LDL cholesterolunder
control (9,10).
American and European guidelines
widely recommend diet, exercise, and
weight counseling with follow-up for
patients with diabetes (11,12). Many
short-term randomized clinical trials
have shown that intensive lifestyle coun-
seling interventions of up to 1 year in du-
ration can lead to lower blood glucose
(13–16) and blood pressure (17–21), but
long-term data on the efﬁcacy of life-
style counseling are lacking(22–24). Fur-
thermore, clinical trials typically involve
resource-intensive interventions that may
not be feasible in routine care, and the
efﬁcacy of lifestyle counseling in everyday
clinical practice remains questionable
(25–27). Consequently, further evidence
is needed to establish that lifestyle coun-
seling as practiced in routine care im-
proves the outcomes of patients with
diabetes.
We therefore conducted a retrospec-
tive study of over 30,000 patients with
diabetes and hyperglycemia, hyperten-
sion, and/or hyperlipidemia who received
care in a primary care setting to test the
hypothesis that higher rates of lifestyle
counseling in routine care are associated
with better diabetes control.
RESEARCH DESIGN AND
METHODSdWe conducted a retro-
spective cohort study to determine the
optimal lifestyle counseling rate for pa-
tients with diabetes. We evaluated the
relationship between the average counsel-
ing rate and time to A1C, blood pressure,
and LDL cholesterol control.
Study cohort
Patients with diabetes seen by primary care
physicians(PCPs)afﬁliatedwiththeBrigham
and Women’s Hospital (BWH) and
Massachusetts General Hospital (MGH) for
at least 2 years between 1 January 2000 and
1 January 2010 were identiﬁed. Patients
were included in the analysis if they were
at least 18 years old, had a documented di-
agnosis of diabetes or hemoglobin A1C
$7.0%, and at least one instance of A1C,
blood pressure, or LDL cholesterol above
treatment target. Patients with missing zip
codes were excluded to enable adjustment
for median household income by zip code.
This study was approved by the Part-
ners HealthCare System institutional re-
view board; the requirement for written
informed consent was waived.
Study measurements
A single uncontrolled period served as the
unit of analysis. We conducted four
analyses: one for each of the three treat-
ment targets (A1C, blood pressure, and
LDL cholesterol) and a combined analysis
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ORIGINAL ARTICLEthatintegratedallthree.Weusedtreatment
goalsrecommendedatthebeginningofthe
study period: A1C ,7.0% (28), blood
pressure ,130/85 mmHg (28,29), and
LDL cholesterol ,100 mg/dL (28). For
analyses of individual treatment targets,
an uncontrolled period started on the day
when the relevant measurement (A1C,
blood pressure, or LDL cholesterol for hy-
perglycemic, hypertensive, and hyperlipi-
demic periods, respectively) was noted to
ﬁrst be above the treatment target. The pe-
riod ended on the ﬁrst subsequent date
when the measurement fell below the tar-
get. As patients’ measures could ﬂuctuate
aboveandbelowtargetmultipletimesdur-
ing the study period, one patient could
contribute more than one period to the
analysis. A combined uncontrolled period
started on the ﬁrst date when any of the
three measures was above the treatment
target and ended on the ﬁrst subsequent
date when all of the measures were below
their targets. Last known value was carried
forwardifallmeasurementswerenotavail-
able on the same date.
The lowest measurement on a given
datewasusedintheanalysis.Lowestblood
pressure was deﬁned as the blood pressure
measurementwiththelowestmeanarterial
pressure.Transientelevationsweredeﬁned
as periods that contained only a single
elevated measurement that subsequently
normalized without any medication inten-
siﬁcationandwereexcludedfromtheanal-
ysis. Uncontrolled periods without at least
one annual encounter with a BWH/MGH
PCP were excluded. Periods without any
medication information available in the
electronic medical record (EMR) were
excluded to enable inclusion of insulin
treatment as a confounder variable in the
analysis. Periods that contained multiple
encounters with an endocrinologist were
excluded to focus the analysis on the pri-
mary care setting. Finally, hyperglycemic
and hyperlipidemic periods where rate of
change of A1C and LDL cholesterol, re-
spectively, was greater than 3 SD from the
mean were excluded to eliminate likely
measurement errors from the analysis.
TimetotargetforA1C,bloodpressure,and
LDL cholesterol during the respective un-
controlled periods was the length of the
uncontrolled period. Lifestyle counseling
instances were deﬁned as distinct days
when a PCP provided diet, exercise, or
weight counseling during theuncontrolled
period. Documentation of lifestyle coun-
seling was computationally abstracted
from the notes, including direct, such as
“stronglyencouragedmorewalking,”and
inferred, for example “weight has gone
up,” instances of lifestyle counseling, as
previously described (30). We inferred
lifestyle counseling if the subject was
Table 1dPatient characteristics
Hyperglycemic period
patients
Hyperlipidemic period
patients
Hypertensive period
patients
Combined uncontrolled
period patients
n 17,404 18,639 30,784 30,897
Age (years)* 60.1 (13.8) 58.4 (13.4) 60.4 (13.9) 59.5 (14.1)
Women, n (%) 8,941 (51.4) 10,301 (55.3) 16,274 (52.9) 16,117 (52.2)
Race/ethnicity, n (%)
White 10,756 (61.8) 11,528 (61.9) 20,882 (67.8) 20,937 (67.8)
Black 2,388 (13.7) 2,544 (13.7) 3,561 (11.6) 3,371 (10.9)
Hispanic 2,494 (14.3) 2,742 (14.7) 3,619 (11.8) 3,684 (11.9)
Other† 1,766 (10.1) 1,825 (9.8) 2,722 (8.8) 2,905 (9.4)
English as the primary
language, n (%) 14,050 (80.7) 15,112 (81.1) 25,745 (83.6) 25,686 (83.1)
Health insurance, n (%)
Private 6,946 (39.9) 8,128 (43.6) 12,611 (41.0) 12,885 (41.7)
Medicare 8,403 (48.3) 8,362 (44.9) 15,100 (49.1) 14,921 (48.3)
Medicaid 1,771 (10.2) 1,872 (10.0) 2,657 (8.6) 2,662 (8.6)
None/unknown 284 (1.6) 277 (1.5) 416 (1.4) 429 (1.4)
Median income by zip
code ($1,000) 52.0 (20.8) 52.5 (21.4) 53.0 (20.6) 53.3 (20.7)
Number of uncontrolled
periods 1.6 (0.9) 1.4 (0.7) 3.7 (2.9) 2.3 (1.9)
Hemoglobin A1C (%) 7.7 (1.2) 7.2 (1.3)
Systolic blood pressure
(mmHg) 130.5 (10.0) 129.5 (10.6)
Diastolic blood pressure
(mmHg) 74.7 (6.7) 74.4 (6.8)
LDL cholesterol (mg/dL) 108.7 (23.2) 99.2 (27.5)
BMI (kg/m
2), mean (SD, % patients
with measures)
32.8
(7.4, 63.2%)
32.6
(7.2, 67.2%)
32.6
(7.3, 66.3%)
32.4
(7.2, 65.1%)
Charlson comorbidity
index 6.2 (4.6) 5.5 (4.5) 5.6 (4.5) 5.4 (4.5)
Follow-up time (months) 80.9 (28.2) 83.3 (28.1) 75.8 (29.5) 74.8 (29.4)
Total time above treatment
target (months) 35.4 (30.0) 37.1 (28.2) 31.2 (24.7) 52.4 (33.6)
Data are mean (SD), unless otherwise indicated. *Age calculated at the start date of the ﬁrst uncontrolled period. †Includes unknown.
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Morrison, Shubina, and Turchinreferredtoinawaythatmadeitlikelythat
itwasdiscussedwiththepatient(e.g.,not
simply weight recorded in the vital signs
section).Thenaturallanguageprocessing
software was previously validated and
had a sensitivity and speciﬁcity that
ranged between 91–97 and 88–94%, re-
spectively. Weight counseling was lim-
ited to periods when the patient had
BMI $30 kg/m
2. During the study pe-
riod, none of the study practices had a
program that encouraged a particular
type of lifestyle counseling or monitored
lifestyle counseling delivered by provid-
ers. To capture both face-to-face and re-
mote interactions between patients and
providers, we deﬁned any note in the EMR
as an encounter and any direct or inferred
mention of lifestyle counseling in the
notes as lifestyle counseling. Dates on
which billing data included Current Pro-
cedural Terminology codes for evaluation
and management were considered face-
to-face lifestyle counseling encounters,
whereas all other instances of lifestyle
counseling were considered remote. Aver-
age lifestyle counseling rate was calculated
bydividing the number ofinstancesoflife-
style counseling by the period length. In
our analyses, we categorized counseling
r a t e sa so n c eo rm o r ep e rm o n t h ,a sl e s s
thanoncepermonthandonceormoreper
6 months, and as less than once per 6
months. Mean encounter interval was de-
termined by dividing the period length by
the number of encounters with PCPs dur-
ing that period. Medication intensiﬁcation
was deﬁned as initiation of a new or an in-
creaseinthedoseofanexistingmedication
(31). Medication intensiﬁcation rate was
deﬁned as the number of unique dates
per month on which at least one medica-
tion in the relevant class was intensiﬁed.
The patient’s PCP was deﬁned as the phy-
sician in a primary care practice who had
the most encounters with the patient dur-
ing the uncontrolled period.
Demographic information, weight,
height, blood pressure measurements,
and medication and laboratory data
were obtained from the EMR at Partners
HealthCaredanintegratedhealthcarede-
livery network in eastern Massachusetts
that includes BWH and MGH.
Statistical analysis
Summary statistics were constructed by
using frequencies and proportions for cat-
egorical data and using means, SDs, me-
dians, and ranges for continuous variables.
Log-ranktestwasusedtocomparetimesto
A1C, blood pressure, and LDL cholesterol
targets between different counseling rates.
Marginal Cox proportional-hazards
model for clustered data (32) was used to
estimate the association between time to
target and lifestyle counseling rate while
accounting for clustering within patient-
provider pairs. Two models were run:
one with an overall lifestyle counseling
rate and one with separate rates for face-
to-face and remote lifestyle counseling.
Themodelsalsoadjustedfordemographic
confounders (age, sex, race, primary lan-
guage, health insurance, and median in-
come by zip code) as well as a patient’s
Charlson comorbidity index (33) for the
periodofthestudy,insulinadministration
as a marker of severity of disease (in hy-
perglycemic and combined uncontrolled
periods), PCP encounter frequency,
medication intensiﬁcation rate, presence
of obesity during the period, A1C and
LDL cholesterol measurement rate and
maximumA1C,systolicbloodpressure,di-
astolicbloodpressure,andLDLcholesterol
(where appropriate). P values were ob-
tained using a type III test.
AllanalyseswereperformedwithSAS
statistical software, version 9.2 (SAS In-
stitute, Inc., Cary, NC).
RESULTSdWeidentiﬁed37,863adults
with diabetes who were regularly seen by
BWH or MGH PCPs and had experienced
at least one hyperglycemic, hypertensive,
or hyperlipidemic period (Supplementary
Fig.). We excluded 6,702 hyperglycemic,
5,760 hypertensive, and 6,428 hyper-
lipidemic patients because of treatment by
endocrinologists;noPCPatBWHorMGH;
Table 2dUncontrolled period characteristics
Hyperglycemic
periods
Hyperlipidemic
periods
Hypertensive
periods
Combined
uncontrolled
periods
Study periods, n 26,984 26,893 112,716 72,532
Period length (months) 22.8 (24.9) 25.7 (25.0) 8.5 (11.7) 22.3 (28.2)
Average initial hemoglobin
A1C (%) 8.1 (1.4)
Average initial LDL cholesterol
(mg/dL) 126.8 (25.4)
Average initial systolic blood
pressure (mmHg) 140.0 (12.8)
Average initial diastolic blood
pressure (mmHg) 78.1 (10.7)
Average maximum
hemoglobin A1C (%) 8.7 (1.9) 7.8 (2.0)
Average maximum LDL
cholesterol (mg/dL) 136.6 (30.5) 111.2 (40.4)
Average maximum systolic
blood pressure (mmHg) 148.4 (17.4) 149.3 (19.6)
Average maximum diastolic
blood pressure (mmHg) 83.8 (10.5) 84.9 (10.9)
Periods wheretreatment target
was reached, n (%)
18,526
(68.7)
20,903
(77.8)
108,737
(92.1)
52,109
(71.9)
Rate of medication
intensiﬁcation per month 0.09 (0.14) 0.06 (0.12) 0.22 (1.1) 0.17 (0.84)
Rate of measure testing per
month 0.23 (0.14) 0.17 (0.17) 1.0 (1.6)
Rate of face-to-face lifestyle
counseling per month 0.24 (0.26) 0.20 (0.23) 0.36 (0.97) 0.24 (0.74)
Rate of remote lifestyle
counseling per month 0.12 (0.20) 0.09 (0.18) 0.20 (0.69) 0.18 (0.60)
Encounter interval (months) 1.9 (1.7) 2.3 (1.9) 1.5 (1.5) 1.9 (1.8)
Periods with patients on
insulin, n (%) 7,194 (26.7) 13,646 (18.8)
Periods with patients who are
obese, n (%) 15,469 (57.3) 15,608 (58.0) 63,837 (56.6) 39,483 (54.4)
Data are mean (SD), unless otherwise indicated.
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Lifestyle counseling and diabetes controlno medication records; only transient ele-
vations in A1C, blood pressure, and LDL
cholesterol; suspected A1C or LDL cho-
lesterol measurement errors; and missing
demographic information. The remaining
17,404 hyperglycemic, 30,784 hyperten-
sive,and18,639hyperlipidemicpatients(a
total of 30,897 unique individuals) were
included in the study.
Study patients (Table 1) did not have
their A1C, blood pressure, or LDL choles-
terol under control 71.3% of the time, and
66% of patients never achieved fullcontrol
during the study period. Their mean initial
A1C, blood pressure, and LDL choles-
terol at the beginning of the respective
uncontrolled periods was 8.1%, 140/78
mmHg, and 126.8 mg/dL (Table 2). Sub-
sequentlymediantimestoreachtreatment
targets ranged from 19 weeks (for hyper-
tensive patients) to over 16 months (for
hyperlipidemic patients). Hyperglycemic
patients had A1C above target a mean of
46.5% of the time, hypertensive patients
haduncontrolledbloodpressure42.0%of
the time, and hyperlipidemic patients had
elevated LDL cholesterol 46.7% of the
time.
Medianface-to-facelifestylecounseling
rates ranged from once every 5.3 months
for hyperglycemic periods to once every 8
months for hypertensive periods, whereas
median remote lifestyle counseling rates
ranged from once every 25 months for hy-
perglycemic periods to never for hyperten-
siveperiods(Table2).Meantimesbetween
patient encounters with a PCP were 1.9
months when hyperglycemic, 1.5 months
when hypertensive, and 2.3 months when
hyperlipidemic. During hyperglycemic pe-
riods,A1Ctestingoccurredonaveragejust
over once every 4 months, blood pressure
was measured once every month during
hypertensive periods, and LDL cholesterol
was measuredonce every6 months during
hyperlipidemic periods. Antihyperglyce-
mic medications were intensiﬁed on av-
erage just over once every 11 months,
Figure 1dLifestyle counseling frequency and time to treatment target. Kaplan-Meier curves for time to treatment target from ﬁrst elevated A1C,
blood pressure, or LDL cholesterol were plotted for different average counseling rates. Distinct uncontrolled periods (from the ﬁrst elevated to the
ﬁrst normal measurement) for the same patient were analyzed separately. A: Lifestyle counseling frequency and time to A1C target. B: Lifestyle
counselingfrequencyandtimetoblood pressuretarget. C:Lifestyle counselingfrequencyandtimeto LDLcholesteroltarget.D:Lifestylecounseling
frequency and time to combined target. DBP, diastolic blood pressure; LDL, LDL cholesterol; SBP, systolic blood pressure.
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Morrison, Shubina, and Turchinantihypertensive medications once every
4.5 months, and antihyperlipidemic med-
ications almost once every 17 months.
Overall, patients with at least one of the
measurements above target had their
treatment intensiﬁed on average once ev-
ery 6 months.
Lifestyle counseling rate and time
to treatment target achievement
Inalltreatmentcategories,timetotreatment
target rose progressively at the less frequent
rates of lifestyle counseling (Fig. 1). Com-
pared with patients with mean face-to-face
counseling rate of once or more per month,
median times to A1C target for patients
whosemeancounselingrateswerebetween
once per 1–6 months and less than once
per 6 months were 3.5 months (95% CI
3.2–3.7) vs. 14.0 (13.6–14.5) vs. 22.7
(21.8–23.5); time to blood pressure target
was 3.7 weeks (3.6–3.7) vs. 5.1 months
(5.1–5.2) vs. 5.6 (5.5–5.7) months and
time to LDL cholesterol target was 3.5
months (3.0–3.8) vs. 15.6 (15.2–16.0) vs.
24.7 (24.1–25.4), respectively. For all
treatment targets combined, median time
to target was 3.9 (3.7–4.0) weeks vs. 13.5
months (13.0–13.9) vs. 13.1 (12.9–13.5)
with mean face-to-face counseling rates of
once or more per month versus once per
1–6 months versus less than once per 6
months.
As counseling rates decreased, the
proportion of patients who never reached
treatment targets rose steadily. Comparing
patients with mean face-to-face counseling
rates of once or more per month to be-
tweenonceper1–6monthsandl essthan
once per 6 months, uncontrolled periods
that never reached treatment target in-
creased from 11.0 to 28 to 35.9% for hy-
perglycemic patients, from 5.63 to 7.2 to
8.86% for hypertensive patients, and from
15.6 to 18.2 to 25.8% for hyperlipidemic
patients. For all treatment targets com-
bined, the proportion of uncontrolled
periods that never achieved all targets
was 9.3% for counseling rates of once or
more per month versus 26.0% for coun-
seling rates between once per 1–6 months
versus 30.5% for counseling rates of less
than once per 6 months.
In multivariable Cox proportional
hazardsmodelsadjustedfordemographic
characteristics,presenceofobesityduring
the uncontrolled period, Charlson co-
morbidity index, insulin administration
(in hyperglycemic and combined uncon-
trolled periods), maximum A1C, systolic
blood pressure, diastolic blood pressure,
and LDL cholesterol (where relevant), rate
Table 3dEffects of patient and treatment characteristics on time to treatment target
Hazard
ratio
95%
Conﬁdence
limits
P value
(x
2)
Hyperglycemic periods
Normalized maximum A1C, per 1% increase 0.539 0.528 0.550 ,0.0001
Normalized age, per 1-year increase 0.993 0.991 0.994 ,0.0001
Female 0.881 0.851 0.911 ,0.0001
Non–English speaker 0.990 0.936 1.046 0.7098
Caucasian 1.000
Black 1.115 1.061 1.171 ,0.0001
Hispanic 1.099 1.028 1.174 0.0058
Asian 1.019 0.934 1.112 0.6658
Other/unknown 0.987 0.919 1.061 0.7310
Income, per $1,000 increase 0.999 0.999 1.000 0.1831
Nonprivate insurance 0.965 0.926 1.005 0.0853
On insulin 0.630 0.602 0.659 ,0.0001
PCP encounter interval, log(months) 0.803 0.770 0.837 ,0.0001
Obesity during period 0.887 0.856 0.920 ,0.0001
Charlson comorbidity index 1.016 1.011 1.020 ,0.0001
Rate of A1C testing, per month 29.812 19.482 45.620 ,0.0001
Rate of antihyperglycemic medication intensiﬁcation,
per month 2.727 2.156 3.450 ,0.0001
Rate of face-to-face lifestyle counseling, per month 1.705 1.422 2.044 ,0.0001
Rate of remote lifestyle counseling, per month 1.699 1.488 1.941 ,0.0001
Hypertensive periods
Normalized maximum systolic blood pressure, per 1-
mmHg increase 0.968 0.968 0.969 ,0.0001
Normalized maximum diastolic blood pressure, per 1-
mmHg increase 0.975 0.974 0.976 ,0.0001
Normalized age, per 1-year increase 0.995 0.994 0.996 ,0.0001
Female 0.938 0.921 0.954 ,0.0001
Non–English speaker 1.035 1.006 1.065 0.0179
Caucasian 1.000
Black 1.150 1.121 1.180 ,0.0001
Hispanic 1.108 1.072 1.144 ,0.0001
Asian 1.175 1.120 1.233 ,0.0001
Other/unknown 1.049 1.010 1.090 0.0128
Income, per $1,000 increase 1.000 1.000 1.000 0.9251
Nonprivate insurance 0.997 0.977 1.018 0.7828
PCP encounter interval, log(months) 0.302 0.298 0.308 ,0.0001
Obesity during period 0.895 0.879 0.910 ,0.0001
Charlson comorbidity index 1.009 1.007 1.012 ,0.0001
Rate of antihypertensive medication intensiﬁcation,
per month 1.625 1.568 1.685 ,0.0001
Rate of face-to-face lifestyle counseling, per month 1.267 1.235 1.301 ,0.0001
Rate of remote lifestyle counseling, per month 1.022 0.981 1.064 0.2933
Hyperlipidemic periods
Normalized maximum LDL cholesterol, per 1-mg/dL
increase 0.974 0.972 0.975 ,0.0001
Normalized age, per 1-year increase 1.007 1.005 1.008 ,0.0001
Female 0.885 0.856 0.916 ,0.0001
Non–English speaker 1.088 1.034 1.144 0.0012
Caucasian 1.000
Black 1.088 1.037 1.140 0.0005
Hispanic 1.142 1.077 1.210 ,0.0001
Asian 1.150 1.062 1.245 0.0006
Other/unknown 1.057 0.968 1.153 0.2151
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(where relevant), visit frequency, and
medication intensiﬁcation, one additional
episode of face-to-face lifestyle counseling
per month was associated with hazard
ratios of 1.7 for A1C control (P , 0.0001)
(Table 3), 1.3 for blood pressure control
(P,0.0001),and1.4forLDLcholesterol
control (P = 0.0013). In multivariable
analysis of combined uncontrolled peri-
ods, an increase of one face-to-face life-
style counseling instance per month was
associated with a hazard ratio of 1.9 for
achieving control of all treatment targets
(P , 0.0001). For most measures, remote
lifestyle counseling rates were also associ-
ated with faster time to target, but hazard
ratios were smaller than those for face-to-
face lifestylecounseling. Acombined face-
to-faceandremotelifestylecounselingrate
analysis was also conducted; results for
this multivariable analysis are provided
in Supplementary Appendix A.
CONCLUSIONSdIn this large, retro-
spective study, we have demonstrated a
strong association between lifestyle coun-
seling and glucose, blood pressure, and
LDL cholesterol control in patients with
diabetes. This association was indepen-
dent of other treatment processes that
could colocalize with lifestyle counseling,
includingfrequencyofpatient-provider
encounters, medication intensiﬁcation,
and rates of A1C or LDL cholesterolmea-
surement.
Several clinical trials have previously
documented the beneﬁt of lifestyle coun-
seling on control of glucose (13–16) and
blood pressure (17–21), but many provid-
ers question whether results of expensive
andtightlycontrolledclinicaltrialsapplyto
theirpractice.Thisstudyprovidesevidence
for the efﬁcacy of lifestyle counseling as
practiced in routine patient care and lends
supporttothecurrenttreatmentguidelines
for patients with diabetes.
Few clinical trials of lifestyle counsel-
ing had follow-up longer than 12 months
(21); this study, with an average length of
follow-up time per patient of almost 7
years, provides evidence for long-term ef-
fects of lifestyle counseling. This is partic-
ularly important because some studies
suggest that effects of intensive diet and
exercise interventions may notbedurable
(24,34,35). Our ﬁndings suggest that, on
the contrary, persistent lifestyle counseling
has lasting effects. Our results conﬁrmed
thatintensivecounselingisneededtoachieve
beneﬁts: the effects of lifestyle counseling
were particularly pronounced in patients
whowerecounseledatleastonceamonth.
Studieshaveshownthatlifestylecoun-
seling in the U.S. remains inadequate
(36–39). Despite the focus on lifestyle
changes in many treatment guidelines,
one study showed no difference in preva-
lence of exercise counseling in a sample
oftheU.S.populationin2002compared
with 1995 (39). Further education of phy-
sicians on the importance of lifestyle coun-
seling and its positive impact on patient
behaviorand healthoutcomes may benec-
essary.Physiciansmayprovidemorecoun-
seling to underserved populations if made
aware that patients with lower income,
lower education level, who are male (37)
andnon–Englishspeaking(38)receivelife-
style counseling at lower rates, compared
with other equally high-risk patients.
Lifestylecounseling is time consuming.
Therefore, implementation of current
guidelines may require modiﬁcation of the
prevalent physician-patient treatment care
model. One option may be to increase the
Table 3dContinued
Hazard
ratio
95%
Conﬁdence
limits
P value
(x
2)
Income, per $1,000 increase 1.001 1.000 1.002 0.0834
Nonprivate insurance 0.992 0.952 1.032 0.6808
PCP encounter interval, log(months) 0.720 0.691 0.750 ,0.0001
Obesity during period 0.888 0.847 0.932 ,0.0001
Charlson comorbidity index 1.009 1.005 1.013 ,0.0001
Rate of LDL cholesterol testing, per month 257.64 114.99 577.26 ,0.0001
Rate of antihyperlipidemic medication
intensiﬁcation, per month 3.600 1.950 6.644 ,0.0001
Rate of face-to-face lifestyle counseling, per month 1.403 1.141 1.726 0.0013
Rate of remote lifestyle counseling, per month 1.215 1.054 1.400 0.0073
Combined uncontrolled periods
Normalized maximum A1C, per 1% increase 0.675 0.667 0.683 ,0.0001
Normalized maximum systolic blood pressure,
per 1-mmHg increase 0.979 0.979 0.980 ,0.0001
Normalized maximum diastolic blood pressure,
per 1-mmHg increase 0.978 0.976 0.979 ,0.0001
Normalized maximum LDL cholesterol,
per 1-mg/dL increase 0.983 0.983 0.984 ,0.0001
Normalized age, per 1-year increase 0.997 0.996 0.998 ,0.0001
Female 0.919 0.899 0.940 ,0.0001
Non–English speaker 1.037 0.997 1.078 0.0693
Caucasian 1.000
Black 1.252 1.208 1.298 ,0.0001
Hispanic 1.187 1.133 1.244 ,0.0001
Asian 1.160 1.088 1.238 ,0.0001
Other/unknown 1.060 1.009 1.114 0.0204
Income, per $1,000 increase 1.002 1.001 1.002 ,0.0001
Nonprivate insurance 1.011 0.985 1.037 0.4155
On insulin 0.894 0.866 0.923 ,0.0001
PCP encounter interval, log(months) 0.726 0.719 0.734 ,0.0001
Obesity during period 0.962 0.941 0.984 0.0007
Charlson comorbidity index 1.037 1.034 1.040 ,0.0001
Rate of A1C testing, per month 1.113 1.069 1.159 ,0.0001
Rate of LDL cholesterol testing, per month 1.160 1.122 1.200 ,0.0001
Rate of antihyperglycemic medication intensiﬁcation,
per month 1.480 1.205 1.817 0.0002
Rate of antihypertensive medication intensiﬁcation,
per month 1.255 1.192 1.321 ,0.0001
Rate of antihyperlipidemic medication intensiﬁcation,
per month 0.955 0.902 1.010 0.1045
Rate of face-to-face lifestyle counseling, per month 1.937 1.836 2.044 ,0.0001
Rate of remote lifestyle counseling, per month 1.615 1.560 1.673 ,0.0001
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practitioners, physician assistants, nutri-
tionists, or exercise physiologists. Another
option may be to implement group coun-
seling sessions in order to more efﬁciently
educate and address patients’ concerns.
This study used advanced compu-
tational technology that permitted cost-
and time-efﬁcient analysis of thousands
of patient records, including examination
of hundreds of thousands of narrative
provider notes in a matter of hours. In the
future, similar technologies could also be
used to monitor quality of patient care
and/or supply feedback to providers.
Our study had several limitations.
The software we used to identify docu-
mentation of lifestyle counseling did not
provide details on the speciﬁcc o u n s e l i n g
approach or the type of diet or exercise
recommended to the patient. However,
littleevidenceexistsforsuperiorityofany
one approach over the others (24,26). It
is therefore likely that multiple different
counseling techniques can be successful,
and speciﬁc type of counseling should be
chosen in accordance with the particular
patient and clinical circumstances. Infor-
mationontheextenttowhichcounseling
followed a structured format (e.g., 5As)
was not obtained because it is frequently
absent in narrative documentation (40).
T h es o f t w a r ew eu s e dd i dn o td i s t i n g u i s h
between lifestyle counseling aimed to ad-
dress hyperglycemia, hypertension, and
hyperlipidemia severally, which may
have led to an overestimate of lifestyle
counseling rates associated with any one
uncontrolledperiod.However,thislackof
speciﬁcityshouldhavebiasedourﬁndings
toward the null hypothesis. In our analy-
sis, we did not analyze individual effects
of diet, exercise, and weight counseling.
However,theireffectsarelikelyoverlapping
because both diet and exercise, for exam-
ple,canleadtoweightloss.Furthermore,
the best approach to counseling may dif-
fer depending on the individual patient
and their readiness to change, rendering
any statement about relative efﬁcacy of
different counseling types moot. We
therefore chose to combine all lifestyle
counseling into a single measure to avoid
this type of confounding. The retrospec-
tivenatureofthisstudydoesnotallowus
to make causal inferences about the rela-
tionship between counseling rates and
time to glucose, blood pressure, and LDL
cholesterol control in patients with diabe-
tes. It could also have led to an analytical
bias. For example, when lifestyle counsel-
ing is sparse, shorter uncontrolled periods
are more likely to have had no counseling
episodes. However, this bias would have
predisposed against the strong inverse as-
sociation between lifestyle counseling and
t h el e n g t ho fu n c o n t r o l l e dp e r i o d st h a tw e
have found. Furthermore, most uncon-
trolled periods in our study were substan-
tially longer than the average observed rate
of lifestyle counseling, making an artifac-
tualassociationbetweenlifestylecounseling
rate and the length of uncontrolled period
unlikely.Additionally,wewereunableto
distinguish between patients with type 1
andtype2diabetes;however,themajority
ofpatientsinthispopulationhavetype2
diabetes, so our ﬁndings may not be ap-
plicable to patients with type 1 diabetes.
In summary, this large long-term ret-
rospective study found that lifestyle coun-
seling isassociated with faster achievement
of A1C, blood pressure, and LDL choles-
terol control in routine patient care, con-
sistent with ﬁndings of randomized
controlled studies. Monthly lifestyle coun-
seling was associated with a particularly
strong effect and could be recommended
forpatientsatparticularlyhighriskofcom-
plications from uncontrolled diabetes. In-
terventional studies are needed to further
establish optimal type and frequency of
lifestyle counseling and its effects on the
micro- and macrovascular complications
of diabetes.
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